Chris Morehouse

Title: Chris Morehouse: Innovator in Biomarker Research

Introduction

Chris Morehouse is a notable inventor based in Gaithersburg, MD (US). He has made significant contributions to the field of biomarker research, particularly in relation to interleukin-23 (IL23)-mediated diseases. With a total of three patents to his name, Morehouse's work has the potential to impact the treatment of conditions such as Crohn's disease.

Latest Patents

Morehouse's latest patents include innovative methods for using CCL20 as a predictor of clinical response to IL23-antagonists. This invention focuses on the use of the Chemokine (C-C motif) ligand 20 (CCL20) as a biomarker to identify patient populations that may respond to anti-IL23 treatments. The patent outlines how levels of CCL20 can help determine patient eligibility for treatment, guide treatment decisions, and predict treatment outcomes. Another significant patent involves the prediction of clinical response to IL23-antagonists using various IL23 pathway biomarkers, including IL22 and lipocalin-2 (LCN2). This invention also aims to stratify patients suffering from IL23-mediated diseases, enhancing the precision of therapeutic interventions.

Career Highlights

Throughout his career, Chris Morehouse has worked with prominent companies in the biotechnology sector, including MedImmune Limited and Amgen Inc. His experience in these organizations has contributed to his expertise in biomarker research and therapeutic development.

Collaborations

Morehouse has collaborated with notable colleagues such as Robert W. Georgantas III and Brandon Higgs. These partnerships have likely enriched his research and innovation efforts in the field.

Conclusion

Chris Morehouse is a distinguished inventor whose work in biomarker research is paving the way for advancements in the treatment of IL23-mediated diseases. His contributions through patents and collaborations highlight his commitment to improving patient outcomes in the medical field.